A new company has been launched to commercialise an award-winning technology, developed at the University of Strathclyde in Glasgow, for tackling bacterial infection and contamination, including superbugs such as MRSA.
Fixed Phage Limited has been established to develop products based on its patented technology for treatment and prevention of infection and bacterial contamination in medicine, food safety, environmental sanitation and many other areas.
Initially the company will focus on wound care applications, and having already proven the technology's effectiveness in a prototype wound closure product, this will be extended to wound dressings able to combat those bacteria causing wound infections, such as MRSA.
The technology enables the powerful anti-bacterial properties of bacteriophages- naturally occurring viruses which are non-toxic to humans, animals and plants but which can destroy bacteria- to be incorporated into new and existing products.
Scottish venture capital company Barwell PLC is providing capital to support the new venture, in partnership with Scottish Enterprise's Scottish Co-Investment Fund, and is hopeful that the company will generate new jobs and opportunities. Working alongside industry, Fixed Phage plans to create, test and produce a wide range of antimicrobial products.
The initial development of the technology was funded through the former Synergy Fund, owned by Strathclyde and the University of Glasgow, and through Scottish Enterprise's Proof of Concept Programme.
Dr Mike Mattey, Honorary Lecturer at the Strathclyde Institute of Pharmacy and Biomedical Sciences and Chief Scientific Officer of Fixed Phage, said: "Bacterial infection is a huge challenge for hospitals and healthcare; and can be at least as harmful to patients as the illnesses they are being treated for.
"We have had highly promising trial results with a prototype and are looking forward to delivering
|Contact: Paul Gallagher|
University of Strathclyde